Measuring Alzheimer disease progression with transition probabilities: Estimates from NACC-UDS

Current Alzheimer Research

Volumn 9, Issue 9, 2012, Pages 1050-1058

  Spackman, D Eldon ^a   Kadiyala, Srikanth ^b   Neumann, Peter J ^c   Veenstra, David L ^b   Sullivan, Sean D ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; Natural history study; Progression; Transition probabilities

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; INSTITUTIONALIZATION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MORTALITY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHILD; DEMENTIA; DISEASE PROGRESSION; HUMANS; INFANT; LOGISTIC MODELS; PROBABILITY; SEVERITY OF ILLNESS INDEX;

EID: 84870187222     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512803569046     Document Type: Article

References (37)

1. FDA-Approved Treatments for Alzheimer's. 2007 [cited 2009 September 24]; Available from: http://www.alz.org/national/documents/topicsheet_treatments.pdf
2. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement 4(2): 110-133 (2008).
3. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148(5): 379-397 (2008).
4. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355(15): 1525-1538 (2006).
5. Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 165(7): 844-854 (2008).
6. Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 52(6): 1138-1145 (1999).
7. McMahon PM, Araki SS, Neumann PJ, Harris GJ, Gazelle GS. Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. Radiology 217(1): 58-68 (2000).
8. McMahon PM, Araki SS, Sandberg EA, Neumann PJ, Gazelle GS. Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology 228(2): 515-522 (2003).
9. Arrighi HM, Neumann PJ, Lieberburg IM, Townsend RJ. Lethality of alzheimer disease and its impact on nursing home placement. Alzheimer Dis Assoc Disord 24(1): 90-95 (2009).
10. Claxton K, Neumann PJ, Araki S, Weinstein MC. Bayesian valueof-information analysis. An application to a policy model of Alzheimer's disease. Int J Technol Assess Health Care 17(1): 38-55 (2001).
11. Dooneief G, Marder K, Tang MX, Stern Y. The Clinical Dementia Rating scale: community-based validation of profound' and terminal' stages. Neurology 46(6): 1746-1749 (1996).
12. Ekman M, Berg J, Wimo A, Jonsson L, McBurney C. Health utilities in mild cognitive impairment and dementia: a population study in Sweden. Int J Geriatr Psychiatry 22(7): 649-655 (2007).
13. Neumann PJ, Araki SS, Arcelus A, Longo A, Papadopoulos G, Kosik KS, et al. Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD. Neurology 57(6): 957-964 (2001).
14. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (3): 189-198 (1975).
15. Hensel A, Angermeyer MC, Riedel-Heller SG. Measuring cognitive change in older adults: reliable change indices for theMini-Mental State Examination. J Neurol Neurosurg Psychiatry 78(12): 1298-1303 (2007).
16. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 40(9): 922-935 (1992).
17. Pfeffer RI, Kurosaki TT, Harrah CH, Jr., Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 37(3): 323-329 (1982).
18. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12): 2308-2314 (1994).
19. Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of memantine on behavioral andpsychological symptoms related to dementia: a systematic metaanalysis. Ann Pharmacother 42(1): 32-8 (2008).
20. Rocca P, Marino F, Montemagni C, Perrone D, Bogetto F. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study. Psychiatry Clin Neurosci 61(6): 622-629 (2007).
21. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a metaanalysis. JAMA 289(2): 210-216 (2003).
22. Liao TF. Interpreting probability models logit, probit and other generalized linear models. Lewis-Beck MS, Ed. Thousand Oaks:Sage Publications 1994.
23. Pampel FC. Logistic regression: a primer. Thousand Oaks: Sage Publications 2000.
24. Oehlert GW. A Note on the delta method. Am Stat 46(1): 27-29 (1992).
25. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 29(1-2): 125-132 (2007).
26. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39(9): 1159-1165 (1989).
27. Helzner EP, Scarmeas N, Cosentino S, Tang MX, Schupf N, Stern Y. Survival in Alzheimer disease: a multiethnic, population-based study of incident cases. Neurology 71(19): 1489-95 (2008).
28. Mehta KM, Yaffe K, Perez-Stable EJ, Stewart A, Barnes D, Kurland BF, et al. Race/ethnic differences in AD survival in USAlzheimer's Disease Centers. Neurology 70(14): 1163-1170 (2008).
29. Steenland K, MacNeil J, Vega I, Levey A. Recent trends in Alzheimer disease mortality in the United States, 1999 to 2004. Alzheimer Dis Assoc Disord 23(2): 165-170 (2009).
30. Paradise M, Cooper C, Livingston G. Systematic review of the effect of education on survival in Alzheimer's disease. IntPsychogeriatr 21(1): 25-32 (2009).
31. Williams MM, Roe CM, Morris JC. Stability of the Clinical Dementia Rating, 1979-2007. Arch Neurol 66(6): 773-7 (2009).
32. Peterson BL, Fillenbaum GG, Pieper CF, Heyman A. Home or nursing home: does place of residence affect longevity in patientswith Alzheimer's disease? The experience of CERAD patients. Public Health Nurs 25(5): 490-497 (2008).
33. National Center for Health Statistics Health, United States, 2007. With Chartbook on Trends in the Health of Americans. Hyattsville, MD 2007.
34. Mittelman MS, Haley WE, Clay OJ, Roth DL. Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease. Neurology 67(9): 1592-1569 (2006).
35. Brodaty H, Mittelman M, Gibson L, Seeher K, Burns A. The effects of counseling spouse caregivers of people with Alzheimerdisease taking donepezil and of country of residence on rates of admission to nursing homes and mortality. Am J Geriatr Psychiatry 17(9): 734-743 (2009).
36. Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry 24(5): 479-488 (2009).
37. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA,et al. Long-term effects of the concomitant use of memantine withcholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80(6): 600-607 (2009).